These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9777973)

  • 1. A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB).
    Knight EV; Oldham JW; Mohler MA; Liu S; Dooley J
    Am J Surg; 1998 Aug; 176(2A Suppl):55S-60S. PubMed ID: 9777973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
    LeGrand EK
    Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of platelet-derived growth factor-BB on bone formation in calvarial defects: an experimental study in rabbits.
    Vikjaer D; Blom S; Hjørting-Hansen E; Pinholt EM
    Eur J Oral Sci; 1997 Feb; 105(1):59-66. PubMed ID: 9085030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Becaplermin gel (Regranex gel)].
    Senet P
    Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in orthopaedic bone repair and regeneration.
    Friedlaender GE; Lin S; Solchaga LA; Snel LB; Lynch SE
    Curr Pharm Des; 2013; 19(19):3384-90. PubMed ID: 23432673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS; Robson MC; Smiell JM; Perry BH
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of recombinant growth factors in wound healing.
    Robson MC; Mustoe TA; Hunt TK
    Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC; Phillips LG; Thomason A; Robson LE; Pierce GF
    Lancet; 1992 Jan; 339(8784):23-5. PubMed ID: 1345953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of becaplermin in the closure of pharyngocutaneous fistulas.
    Jakubowicz DM; Smith RV
    Head Neck; 2005 May; 27(5):433-8. PubMed ID: 15776464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release, biological potency, and biochemical integrity of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) combined with Augment(TM) Bone Graft or GEM 21S beta-tricalcium phosphate (beta-TCP).
    Young CS; Ladd PA; Browning CF; Thompson A; Bonomo J; Shockley K; Hart CE
    J Control Release; 2009 Dec; 140(3):250-5. PubMed ID: 19577598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone.
    Nevins M; Camelo M; Nevins ML; Schenk RK; Lynch SE
    J Periodontol; 2003 Sep; 74(9):1282-92. PubMed ID: 14584860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-derived growth factor-BB accelerates wound closure in a new mesentery culture model without macrophages.
    Wu L; Kumar SB; Porras-Reyes BH; Gramates PH; Mustoe TA
    Ann Plast Surg; 1994 Aug; 33(2):155-61. PubMed ID: 7979047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of a rotator cuff suture repair using rhPDGF-BB and a type I bovine collagen matrix in an ovine model.
    Hee CK; Dines JS; Dines DM; Roden CM; Wisner-Lynch LA; Turner AS; McGilvray KC; Lyons AS; Puttlitz CM; Santoni BG
    Am J Sports Med; 2011 Aug; 39(8):1630-9. PubMed ID: 21555508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.